What’s the End Game? Rethinking Prostate Cancer Screening, Biopsy, and Treatment

Most men believe they are making rational decisions when it comes to prostate cancer. They believe they are following the science, trusting the experts, and doing what is necessary to protect themselves. On the surface, the process appears logical and reassuring. PSA rises, concern follows, a urology appointment is scheduled, and a prostate biopsy is recommended. If cancer is identified, the conversation quickly shifts toward surgery, radiation, hormone therapy, or active surveillance. The entire pathway feels systematic, modern, and evidence-based, giving men the impression that each step naturally leads to the next.

But there is one question almost nobody stops to ask: what is the end game?

That question is much bigger than what happens next week, what the next PSA result shows, or what the MRI may reveal. The real question is where this entire path is ultimately leading. What outcome are we actually working toward, and more importantly, what are we sacrificing to get there?

That question should matter to every man facing prostate cancer decisions. Unfortunately, most men never pause long enough to ask it because fear enters the conversation early and changes the way decisions are made. Once fear takes over, thoughtful analysis often gets replaced by urgency. The objective becomes simple: find the cancer, treat the cancer, eliminate the cancer, and do it quickly.

But what if the strategy itself deserves more scrutiny? What if the path many men are pushed onto often creates more harm than benefit?

That is not an easy conversation because it challenges assumptions that have become deeply embedded in modern prostate cancer care. It forces us to look beyond short-term goals and ask harder questions about long-term outcomes. If the end result of treatment is a man who survives but loses vitality, sexual function, physical strength, independence, and quality of life without clear evidence of improved survival, then we need to be honest enough to ask whether the strategy truly makes sense.

That is the uncomfortable conversation modern prostate cancer care largely avoids, and it is exactly the conversation we need to have.

The Uncomfortable Truth About Prostate Cancer

The average man hears the word cancer and immediately thinks of something aggressive, dangerous, and rapidly progressive. That reaction is understandable because most cancers carry enormous emotional weight. The word itself creates fear. But prostate cancer is different, and understanding that difference is critical.

For decades, autopsy studies have shown something extraordinary about prostate cancer. Research published in the Journal of the National Cancer Institute found microscopic prostate cancer in more than 40% of men over age 60, reaching nearly 60% in men over age 80. Yet many of these men never developed symptoms, metastatic disease, or died from prostate cancer. This is why the distinction matters: many men die with prostate cancer, not from it.

If abnormal prostate cells are this common, and if most men never suffer meaningful harm from them, then we need to ask a much more thoughtful question when prostate cancer is diagnosed: what exactly are we detecting?

I often refer to these as atypical dormant cells. These are abnormal cells that may remain biologically quiet for years or even decades. They may exist without meaningful progression. They may never threaten life. They may never require aggressive intervention. The problem is that once these cells are identified and labeled as cancer, the entire emotional trajectory changes almost instantly.

This is one of the central problems with modern prostate cancer screening. The issue is not necessarily screening itself. The issue is what happens after screening. The PSA test is not the enemy. PSA is simply information. It is a signal and a risk marker, not a diagnosis and certainly not a treatment plan. Even the National Cancer Institute acknowledges that elevated PSA can occur from benign enlargement, inflammation, infection, and other non-cancer causes.

Unfortunately, many men hear the words “your PSA is elevated” and immediately assume they are headed toward biopsy, diagnosis, and treatment. That assumption deserves to be challenged because an elevated PSA does not automatically mean dangerous cancer, and a diagnosis does not automatically mean aggressive treatment improves outcomes.

When Detection Becomes the Problem

One of the most deeply ingrained assumptions in modern medicine is that earlier detection automatically leads to better outcomes. On the surface, that sounds entirely reasonable. Find disease earlier, intervene earlier, and improve survival. That logic has shaped much of modern screening and diagnostic medicine, particularly in prostate cancer.

Modern medicine has become extraordinarily skilled at detecting abnormalities. We can identify smaller lesions, subtler imaging findings, and earlier biological changes than ever before. Technological advances in PSA testing, MRI imaging, and diagnostic screening have made it possible to find abnormalities long before they would have become clinically apparent. This is often presented as unquestionable progress, and in some situations it is. But better detection does not automatically translate into better outcomes. That distinction is critically important, and it is where much of the logic surrounding prostate cancer begins to break down.

The issue is not whether we can detect abnormalities within the prostate. We clearly can. The real challenge is determining which abnormalities are clinically meaningful and which are not. That is a far more difficult question, and unfortunately it is one medicine that still struggles to answer with confidence.

For decades, the dominant narrative has been straightforward: detect prostate cancer early, treat it aggressively, and save lives. It sounds logical, but prostate cancer has always resisted simplistic thinking. Not every lesion is dangerous. Not every abnormality is destined to progress. Not every cancer diagnosis leads to suffering, metastasis, or death.

That is where uncertainty enters the conversation, and both physicians and patients tend to be uncomfortable with uncertainty. Patients want clarity. Physicians want certainty. Uncertainty creates anxiety, and anxiety creates pressure to act. Do something. Remove something. Treat something. Intervention feels productive. It feels reassuring. It creates the impression of control. But action itself carries consequences.

That is the part of the conversation that is often minimized. Men are understandably focused on survival, and physicians are understandably focused on reducing risk. Yet far less attention is often given to what life looks like after intervention. What happens to urinary function? What happens to sexual function? What happens to vitality, strength, independence, and quality of life?

This is why detection alone should never be mistaken for benefit. Finding an abnormality is only useful if acting on that information meaningfully improves outcomes that matter. If detection simply leads to more biopsies, more procedures, more side effects, and more harm without significantly improving long-term survival, then we need to be willing to question whether detection alone is truly helping the patient.

This is exactly what long-term prostate cancer research has forced us to confront. The landmark ProtecT trial and PIVOT trial found minimal differences in prostate cancer mortality between men who underwent aggressive treatment and those managed with observation over long-term follow-up. What differed more significantly was quality of life, particularly urinary, sexual, and bowel function.

The real question is not whether we can detect prostate abnormalities earlier. The real question is whether earlier detection meaningfully improves the outcomes men care about most. If it does not, then earlier detection may simply mean earlier anxiety, earlier intervention, and earlier harm.

Does Prostate Cancer Treatment Improve Survival?

This is perhaps the most uncomfortable question in all of prostate cancer care, and it is a question every man deserves to ask before making a life-changing treatment decision. Most men assume surgery or radiation clearly improves survival. They believe removing the prostate or aggressively treating the tumor significantly changes long-term mortality. Many physicians operate under the same assumption because it feels intuitive. Find the cancer. Remove the cancer. Improve survival.

The problem is the evidence is far more complicated.

The 15-year ProtecT trial published in NEJM produced data that should force every physician and every patient to think more carefully about prostate cancer treatment. Men assigned to active monitoring, surgery, and radiation all had remarkably low prostate cancer-specific mortality over long-term follow-up. In other words, whether men underwent aggressive intervention or careful monitoring, prostate cancer death rates remained similarly low across all groups.

The assumption that immediate aggressive treatment automatically improves survival becomes much harder to defend when long-term outcomes look so similar.

The PIVOT trial, reached similar conclusions. For many men with localized prostate cancer, surgery offered little to no meaningful survival advantage compared with observation. That should concern every man considering aggressive treatment because it challenges one of the most deeply accepted assumptions in prostate cancer care.

Aggressive prostate cancer exists, and some men absolutely require intervention. There are cases where treatment is appropriate and necessary. But the assumption that every detected prostate cancer benefits from aggressive treatment is simply not supported by the evidence.

What we do know with certainty is that treatment carries real harm. Surgery, radiation, and hormone therapy all carry significant downstream consequences that can profoundly affect quality of life. Urinary incontinence, erectile dysfunction, loss of libido, fatigue, depression, muscle loss, weight gain, and loss of confidence are not rare complications. They are common consequences that can alter how a man functions physically, emotionally, and psychologically for years.

That brings us back to the same question.

What is the end game?

If a man lives roughly the same number of years but loses function, vitality, independence, sexual health, and quality of life along the way, was that truly a better outcome? Because in prostate cancer care, survival alone is not the only outcome that matters. How a man lives matters too.

Why Prostate Biopsy Deserves More Scrutiny

One of the most common questions I hear from men is simple: should I get a prostate biopsy? For many, the assumption is that biopsy is simply the next logical step. PSA rises, concern follows, and biopsy is presented as routine, almost automatic. The recommendation is often delivered in a way that makes declining the procedure feel irresponsible or reckless, as though saying no means ignoring a serious threat. I strongly disagree with how casually this decision is often presented.

A prostate biopsy is not a trivial event. It is an invasive procedure with real physical and psychological consequences. Whether performed transrectally or transperineally, biopsy involves repeatedly driving large core needles into a vascular organ. That carries real risk. Pain, bleeding, infection, urinary retention, and hospitalization are all possible complications. In some cases, serious infections and sepsis occur. They are well documented in the literature. A systematic review published in European Urology found meaningful rates of both infectious and noninfectious complications following prostate biopsy, reinforcing that this is far more than a routine diagnostic test. But the physical risks, while important, are only part of the story. The greater consequence often begins the moment the pathology report comes back with one word: cancer.

Even when the findings suggest low-grade disease, even when the lesion appears slow growing, and even when the biology suggests it may never become clinically significant, the emotional landscape shifts almost immediately. Fear enters the room, and once fear enters, decision-making changes. Men who felt relatively calm before biopsy often begin to panic. Families panic. Spouses panic. Adult children panic. Pressure builds quickly, and suddenly the conversation shifts from thoughtful analysis to urgent action. This is where logic often begins to break down.

The man who felt healthy yesterday may now feel as though his life is in immediate danger. He often feels pushed toward major decisions before fully understanding what the diagnosis actually means, what the true risks are, or what the long-term consequences of treatment may be. The emotional weight of diagnosis often drives decisions far more than the actual biology of the disease.

This is precisely why I believe prostate biopsy deserves far more thoughtful discussion than most men are given. The real question is not whether biopsy can identify cancer. The more important question is whether identifying that cancer meaningfully improves the final outcome. 

The Hidden Cost of Hormone Suppression

This brings us to one of the most concerning areas in modern prostate cancer treatment: androgen deprivation therapy, commonly called ADT or hormone therapy. While the term hormone therapy sounds relatively benign, the reality is far more serious. ADT works by dramatically suppressing testosterone levels, essentially creating a state of chemical castration. That phrase makes many people uncomfortable, but perhaps it should, because the physiological consequences are profound.

The logic behind ADT appears straightforward. Prostate cancer cells often respond to androgens, particularly testosterone. Lower testosterone aggressively, and cancer growth may slow. Testosterone is not merely a hormone related to sexual function. It is deeply tied to male vitality. It influences muscle mass, energy, metabolism, motivation, mood, cognition, cardiovascular health, and physical resilience. Remove it, and predictable consequences follow.

Men undergoing ADT commonly experience fatigue, loss of muscle mass, increased body fat, weight gain, insulin resistance, depression, cognitive changes, reduced motivation, and loss of libido. Sexual function often declines dramatically or disappears entirely. A review on the adverse effects of androgen deprivation therapy describes many of these effects, including changes in body composition, lipid metabolism, insulin sensitivity, bone health, and quality of life.

The metabolic consequences are equally troubling. Studies have linked ADT with increased risk of diabetes, cardiovascular disease, osteoporosis, and fractures. A review in Bone and Metabolic Health in Men Receiving ADT highlights increased risks of osteoporotic fractures, type 2 diabetes, and possibly cardiovascular disease in men receiving ADT. Additional research has also found associations between ADT and cardiovascular adverse effects, including myocardial infarction and stroke, reinforcing that testosterone suppression is not a small intervention. It affects the entire man.

We are often imposing predictable and significant harm in exchange for benefits that are not always clear, durable, or meaningful in terms of overall survival and quality of life. 

I am not suggesting there is never a role for ADT. There are clinical scenarios where hormone suppression may be appropriate. The problem is not that ADT exists. The problem is how casually its consequences are often presented during the decision-making process. Too often, the discussion becomes narrowly focused on suppressing PSA, shrinking lesions, or slowing disease markers, while insufficient attention is given to the human cost of that intervention.

This is where modern medicine often falls into a dangerous trap. We become so focused on treating the disease that we lose sight of the person living with the treatment. Men are not PSA values. Men are not lab markers. Men are human beings with lives, families, responsibilities, goals, and identities. That perspective should remain central to every treatment decision, especially when the treatment itself carries such profound consequences.

The Danger of Treating Numbers Instead of Men

One of the greatest weaknesses in modern medicine is its growing obsession with numbers. Lower the PSA. Lower the cholesterol. Lower the glucose. Lower the marker. Numbers matter, of course. They provide useful information and can help guide decision-making. But numbers are not the ultimate objective. Health is the objective. Function is the objective. Vitality is the objective.

This distinction is critical because modern medicine often confuses improving a number with improving a human life. Sometimes lowering a marker leads to better outcomes. Sometimes it does not. That is where the logic often breaks down. Medicine has become increasingly reliant on surrogate endpoints, measurable laboratory values that are assumed to predict meaningful health outcomes. But a better lab value does not always translate into better health, better function, or longer life. 

This problem is particularly evident in prostate cancer care. A PSA rises and panic often follows. Treatment is escalated. Hormones are suppressed. Procedures are recommended. The focus quickly shifts toward lowering PSA at all costs. But lowering PSA is not necessarily the same as improving survival, preserving function, or protecting quality of life.

The long-term data should force us to think more critically. The ProtecT trial demonstrated remarkably low prostate cancer mortality across active monitoring, surgery, and radiation groups despite dramatically different treatment strategies. That finding should cause every physician and every patient to pause and ask a difficult question: what exactly are we trying to optimize?

I have seen too many men aggressively treated based primarily on numbers while their overall vitality steadily declines. They become weaker, more fatigued, less functional, and less resilient. They lose muscle mass. They gain fat. Their energy drops. Their mental clarity suffers. Their lab values may look improved on paper, yet the person sitting in front of you is clearly deteriorating.

What exactly are we calling success?

That question deserves honest reflection because medicine should never lose sight of the bigger picture. A lower PSA may look reassuring on paper, but if the cost is profound loss of vitality, function, and quality of life, then we need to ask whether we are truly helping the patient or merely improving a number.

What Is the Smarter Path Forward?

The answer is not denial. The answer is not pretending aggressive prostate cancer does not exist, nor is it avoiding information or ignoring risk. The smarter path is not about doing less simply for the sake of doing less. It is about making better decisions. That begins by rejecting fear-based medicine.

Fear is one of the most powerful forces in prostate cancer care, and unfortunately, it drives many of the worst decisions. Fear creates urgency where urgency may not exist. Fear narrows perspective and pushes men toward irreversible interventions before they fully understand the long-term consequences. Once fear takes hold, thoughtful decision-making becomes much more difficult.

The smarter path begins with clarity. That means slowing down long enough to understand the full picture. Men need to understand their PSA trend, not just a single PSA value. They need to understand their MRI findings, overall health, metabolic status, hormone profile, symptoms, and true level of risk. Most importantly, they need to recognize that prostate health does not exist in isolation.

This is where conventional medicine often gets it wrong. The prostate is not some isolated organ operating independently from the rest of the body. It exists within a complex biological system where inflammation, metabolic health, hormone status, muscle mass, cardiovascular function, and insulin resistance all interact. When you start to see the body as an integrated system rather than a collection of separate parts, you begin to understand why prostate health is about much more than the prostate alone.

This is why I believe prostate cancer should be approached through a broader and more thoughtful framework. The goal should not simply be suppressing numbers or reacting emotionally to fear-driven narratives. The real objective is preserving vitality, strength, function, and quality of life while intelligently managing risk.

That requires thoughtful surveillance, strategic monitoring, and deliberate decision-making. Not passivity. Not panic. Strategy. That is what intelligent prostate care should look like.

The Question Every Man Must Ask

Before agreeing to a prostate biopsy, surgery, radiation, or hormone suppression, every man should stop and ask one simple but profoundly important question: what is the end game? Not what happens next week. Not what the next PSA result shows. Not what procedure is being recommended today. The real question is where this path ultimately leads and what the long-term outcome is likely to look like.

That question changes everything because it forces men to think beyond the immediate fear of a diagnosis and toward the long-term consequences of their decisions. Too often, men become narrowly focused on the next step. The next PSA. The next MRI. The next appointment. The next procedure. They become so consumed by what happens next that they never pause to ask where the entire path is leading.

The ultimate goal should never be survival at any cost. Extending life is a worthy goal, but not if the price is sacrificing the very things that make life meaningful. Strength matters. Vitality matters. Independence matters. Dignity matters. Quality of life matters. These are not secondary considerations. They are central to the decision.

We are all ultimately mortal. None of us escapes that reality. The goal is not immortality. The goal is to live as long as possible with strength, clarity, resilience, and purpose. That is the real end game.

This is why every major decision in prostate cancer care deserves thoughtful analysis and honest scrutiny. Men should understand not only the potential benefits of treatment, but also the costs, tradeoffs, and long-term consequences. Too often, fear drives men toward irreversible decisions before they fully understand the path they are choosing.

Sometimes the smartest decision in medicine is not what you choose to do next. Sometimes the smartest decision is what you choose not to do.

If you want a more thoughtful framework for thinking about prostate cancer screening, biopsy, and treatment decisions, watch Dr. Stephen Petteruti’s full podcast here, What’s the End Game? Rethinking Prostate Cancer Screening and Strategy, to better understand how to approach these decisions with more clarity, strategy, and confidence.

About Dr. Stephen Petteruti

Dr. Stephen Petteruti is a physician focused on men’s health, hormone optimization, longevity, and prostate cancer care. His approach challenges conventional thinking by focusing on root causes, metabolic health, and long-term vitality. His goal is not simply helping patients live longer, but helping them preserve strength, energy, resilience, and quality of life as they age.

Learn more at Dr. Stephen Petteruti

References

1. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011;194(6):301-306. doi:10.5694/j.1326-5377.2011.tb02979.x
2. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220
3. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876-892. doi:10.1016/j.eururo.2013.05.049
4. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010;8(2):211-223. doi:10.6004/jnccn.2010.0014
5. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203-213. doi:10.1056/NEJMoa1113162
6. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105(14):1050-1058. doi:10.1093/jnci/djt151